Merck KGaA (ETR: MRK), a German multinational pharmaceutical, chemical, and life sciences company, has this week unveiled new clinical data for its cytotoxic drug Mavenclad (cladribine) in the treatment of highly active relapsing multiple sclerosis (RMS). The results indicate that over 95% of participants noted clinically meaningful improvements in cognitive processing speed two years into the treatment.
Furthermore, follow-up data collected one year post-treatment completion revealed that 77% and 86% of patients, with and without prior therapy respectively, experienced no relapses, disease progression, or brain lesions. These statistics underscore the sustained efficacy of Mavenclad in managing RMS.- Flcube.com
